Quick Links

Clinical Trials


Clinical Research Program (CRP) – McGill’s Department of Oncology

The CRP offers patients the opportunity to participate in studies that incorporate new state-of-the-art therapeutic treatments and, most importantly, to provide patients with the best possible care from the time of diagnosis onward.

In existence for more than 20 years, the CRP continues to grow in scope and has served hundreds of sponsors, with a client base of large pharmaceutical firms as well as smaller companies. The CRP draws on patients, staff and resources of the three McGill affiliated hospitals engaged in oncology: the McGill University Health Centre, the Jewish General Hospital and St. Mary’s Hospital.

Advantages:

  • Phase I, II and III studies in all cancers and leukemias;
  • the gateway to all clinical oncology activities of McGill’s teaching hospitals;
  • high rate of patient recruitment;
  • single clinical trial agreement and one ethics review; and
  • study results accepted by Health Canada, the FDA and the EMEA.

 

For more information on clinical trials currently underway, please see Clinical Research Program.


Clinical Research Unit (CRU) – The Montreal Neurological Institute (MNI)

The MNI is one of the world’s leading institutions dedicated to clinical and basic research in neuroscience. The CRU specializes in conducting clinical trials for neurological diseases. It has been doing so since 1986, and was a major participant in the trials that led to the first approved medications for Multiple Sclerosis.

The CRU is dedicated to:

  • Aiding the advancement of neuroscience through clinical research;
  • participating in clinical trials to identify new or more effective treatments;
  • supplying study subjects with the best quality of care; and
  • providing high quality data to sponsors and investigators.

The CRU’s experience includes trials for neurological diseases such as Multiple Sclerosis, Amyotrophic Lateral Sclerosis, epilepsy, Parkinson's Disease, stroke, neuromuscular diseases, brain tumours, neuropathic pain and migraines. Furthermore, the CRU has access to the most advanced medical technologies available today.

Advantages:

  • Phase I, II, III and IV studies;
  • access to the McConnell Brain Imaging Centre, one of the largest of its kind in the world; and
  • study results accepted by Health Canada, the FDA and the EMEA.

 

For more information on clinical trials currently underway, please see Clinical Research Unit.


Psychiatry (Allan Memorial Institute)

marie-claire [dot] belanger [at] mcgill [dot] ca (Marie-Claire Belanger) , RN
Associate Director, Clinical Research
Clinical Psychopharmacology Unit
Tel: 514-398-7305

McGill conducts Phase I, II, III and IV trials on a fee for service arrangement. In these studies the sponsor owns the protocol and drug or device, publications will be delayed to protect commercial interests or reporting by all participating centres (not to exceed one year), confidentiality provisions will be required, and indemnification and insurance provisions are reviewed with particular care.

For more information on clinical trial agreements, please contact an OSR Contracts and Agreements Officer or the appropriate CRU/CRP representative.

Classified as